Agenus vs Monte Rosa Therapeutics
Monte Rosa Therapeutics reported revenue of $124 million in fiscal 2025, about the same as Agenus' $114 million in fiscal 2025. Agenus' revenue grew 10.4% in its latest year, and Monte Rosa Therapeutics' grew 63.5%. Agenus had an operating margin of -17.7%, against -43.8% at Monte Rosa Therapeutics. Free cash flow was −$77 million at Agenus and −$28 million at Monte Rosa Therapeutics.
Side by side
| Agenus | Monte Rosa Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $114M | $124M |
| Revenue growth | 10.4% | 63.5% |
| Revenue growth a year, last 5 years | 5.3% | — |
| Gross margin | 99.1% | — |
| Operating margin | −17.7% | −43.8% |
| Net margin | −2.7% | −31.2% |
| Free cash flow | −$77M | −$28M |
| Free cash flow margin | −67.6% | −22.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 38.5% | 12.4% |
| Last close | $6.14 | $8.91 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $4.0 million |
| Piotroski F-score | 3 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AgenusMonte Rosa Therapeutics
Operating margin
Percent of revenue
AgenusMonte Rosa Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AgenusMonte Rosa Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agenus and Monte Rosa Therapeutics pages.